SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999; 92: 2118.
  • 2
    Austin HA III, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, et al. Prognostic factors in lupus nephritis: contribution of renal histologic data. Am J Med 1983; 75: 38291.
  • 3
    Moroni G, Pasquali S, Quaglini S, Banfi G, Casanova S, Maccario M, et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 1999; 34: 5309.
  • 4
    Austin HA III, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994; 45: 54450.
  • 5
    Austin HA III, Boumpas DT, Vaughan EM, Balow JE. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995; 10: 16208.
  • 6
    Dooley MA, Hogan S, Jennette C, Falk R, Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997; 51: 118895.
  • 7
    Magil AB, Puterman ML, Ballon HS, Chan V, Lirenman DS, Rae A, et al. Prognostic factors in diffuse proliferative lupus glomerulonephritis. Kidney Int 1988; 34: 5117.
  • 8
    Nossent HC, Henzen-Logmans SC, Vroom TM, Berden JH, Swaak TJ. Contribution of renal biopsy data in predicting outcome in lupus nephritis: analysis of 116 patients. Arthritis Rheum 1990; 33: 9707.
  • 9
    McLaughlin JR, Bombardier C, Farewell VT, Gladman DD, Urowitz MB. Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. Arthritis Rheum 1994; 37: 55967.
  • 10
    Conlon PJ, Fischer CA, Levesque MC, Smith SR, St Clair EW, Allen NB, et al. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol 1996; 46: 1705.
  • 11
    Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59: 215663.
  • 12
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 63040.
  • 13
    Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 68995.
  • 14
    Laitman RS, Glicklich D, Sablay LB, Grayzel AI, Barland P, Bank N. Effect of long-term normalization of serum complement levels on the course of lupus nephritis. Am J Med 1989; 87: 1328.
  • 15
    Mosca M, Pasquariello A, Tavoni A, Moriconi L, Moneta I, Innocenti M, et al. Predictors of renal outcome in diffuse proliferative glomerulonephritis in systemic lupus erythematosus. Lupus 1997; 6: 3718.
  • 16
    Decker JL, Steinberg AD, Reinertsen JL, Plotz PH, Balow JE, Klippel JH. NIH conference: Systemic Lupus Erythematosus: Evolving Concepts. Ann Intern Med 1979; 91: 587604.
  • 17
    Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D. Long-term follow-up of patients with lupus nephritis: a study based on the classification of the World Health Organization. Am J Med 1987; 83: 87785.
  • 18
    Schwartz MM, Bernstein J, Hill GS, Holley K, Phillips EA, Lupus Nephritis Collaborative Study Group. Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis. Kidney Int 1989; 36: 8916.
  • 19
    Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ, Lupus Nephritis Collaborative Study Group. Role of pathology indices in the management of severe lupus glomerulonephritis. Kidney Int 1992; 42: 7438.
  • 20
    Valeri A, Radhakrishnan J, Estes D, D'Agati V, Kopelman R, Pernis A, et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994; 42: 718.
  • 21
    Hill GS, Delahousse M, Nochy D, Remy P, Mignon F, Mery JP, et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 2001; 59: 30416.
  • 22
    Baldwin DS, Lowenstein J, Rothfield NF, Gallo G, McCluskey RT. The clinical course of the proliferative and membranous forms of lupus nephritis. Ann Intern Med 1970; 73: 92942.
  • 23
    Ginzler EM, Nicastri AD, Chen CK, Friedman EA, Diamond HS, Kaplan D. Progression of mesangial and focal to diffuse lupus nephritis. N Engl J Med 1974; 291: 6936.
  • 24
    Morel-Maroger L, Mery JP, Droz D, Godin M, Verroust P, Kourilsky O, et al. The course of lupus nephritis: contribution of serial renal biopsies. Adv Nephrol Necker Hosp 1976; 6: 79118.
  • 25
    Baldwin DS, Gluck MC, Lowenstein J, Gallo GR. Lupus nephritis: clinical course as related to morphologic forms and their transitions. Am J Med 1977; 62: 1230.
  • 26
    Cameron JS, Turner DR, Ogg CS, Williams DG, Lessof MH, Chantler C, et al. Systemic lupus with nephritis: a long-term study. QJM 1979; 48: 124.
  • 27
    Derksen RH, Hene RJ, Kater L. The long-term clinical outcome of 56 patients with biopsy-proven lupus nephritis followed at a single center. Lupus 1992; 1: 97103.
  • 28
    Yoo CW, Kim MK, Lee HS. Predictors of renal outcome in diffuse proliferative lupus nephropathy: data from repeat renal biopsy. Nephrol Dial Transplant 2000; 15: 16048.
  • 29
    Zimmerman SW, Jenkins PG, Shelf WD, Bloodworth JM Jr, Burkholder PM. Progression from minimal or focal to diffuse proliferative lupus nephritis. Lab Invest 1975; 32: 66572.
  • 30
    Appel GB, Silva FG, Pirani CL, Meltzer JI, Estes D. Renal involvement in systemic lupus erythematosus (SLE): a study of 56 patients emphasizing histologic classification. Medicine (Baltimore) 1978; 57: 371410.
  • 31
    Lee HS, Mujais SK, Kasinath BS, Spargo BH, Katz AI. Course of renal pathology in patients with systemic lupus erythematosus. Am J Med 1984; 77: 61220.
  • 32
    Balow JE, Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Klippel JH, et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984; 311: 4915.
  • 33
    Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The pathogenesis and prognosis of lupus nephritis: information from repeat renal biopsy. Semin Arthritis Rheum 1993; 23: 13548.
  • 34
    Tam LS, Li EK, Leung CB, Wong KC, Lai FM, Wang A, et al. Long-term treatment of lupus nephritis with cyclosporin A. QJM 1998; 91: 57380.
  • 35
    Gunnarsson I, Sundelin B, Heimburger M, Forslid J, van Vollenhoven R, Lundberg I, et al. Repeated renal biopsy in proliferative lupus nephritis—predictive role of serum C1q and albuminuria. J Rheumatol 2002; 29: 6939.
  • 36
    Ding L, Zhao M, Zou W, Liu Y, Wang H. Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study. Lupus 2004; 13: 1138.
  • 37
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50: 3934-40.
  • 38
    Pillemer SR, Austin HA III, Tsokos GC, Balow JE. Lupus nephritis: association between serology and renal biopsy measures. J Rheumatol 1988; 15: 2848.
  • 39
    Bajaj S, Albert L, Gladman DD, Urowitz MB, Hallett DC, Ritchie S. Serial renal biopsy in systemic lupus erythematosus. J Rheumatol 2000; 27: 28226.
  • 40
    Hill GS, Delahousse M, Nochy D, Tomkiewicz E, Remy P, Mignon F, et al. A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 2000; 58: 116073.
  • 41
    Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake A, de Glas-Vos JW, Bijl M, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis: a randomized controlled trial. Kidney Int 2006; 70: 73242.
  • 42
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 43
    Churg J, Bernstein J, Glassock RJ. Renal disease: classification and atlas of glomerular diseases. New York: Igaku-Shoin; 1995.
  • 44
    Fleiss JL. The measurement of interrater agreement. In: FleissJL, editor. Statistical methods for rates and proportions. New York: John Wiley & Sons; 1981. p. 21236.
  • 45
    Nagelkerke NJ. A note on a general definition of the coefficient of determination. Biometrika 1991; 78: 6912.
  • 46
    Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 52130.
  • 47
    Favre H, Miescher PA, Huang YP, Chatelanat F, Mihatsch MJ. Ciclosporin in the treatment of lupus nephritis. Am J Nephrol 1989; 9 Suppl 1: 5760.
  • 48
    Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000; 136: 2437.
  • 49
    Jacobsen S, Starklint H, Petersen J, Ullman S, Junker P, Voss A, et al. Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine. Scand J Rheumatol 1999; 28: 28899.
  • 50
    Esdaile JM, Abrahamowicz M, MacKenzie T, Hayslett JP, Kashgarian M. The time-dependence of long-term prediction in lupus nephritis. Arthritis Rheum 1994; 37: 35968.
  • 51
    Chan TM, Tse KC, Tang CS, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14: 26572.
  • 52
    Hill GS, Delahousse M, Nochy D, Thervet E, Vrtovsnik F, Remy P, et al. Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy. Kidney Int 2002; 61: 217686.